Peter Wehrwein


Trikafta Effective But Costly, Says Prime Therapeutics

October 17, 2022

A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.

Researchers: Ancillary Services Would Comprise 20% of Medicare Spending on Aduhelm

January 15, 2022

In a research letter published in JAMA Health Forum, researchers say most of the cost figures for Aduhelm have left out the additional MRI scans and other services that will be required because the drug is associated with the development of amyloid-related imaging abnormalities (ARIAs).